Morgan Stanley Galectin Therapeutics Inc Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Morgan Stanley holds 246,080 shares of GALT stock, worth $509,385. This represents 0.0% of its overall portfolio holdings.

Number of Shares

246,080

Previous 227,217 8.3%

Holding current value

$509,385

Previous $513,000 31.77%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.04 - $2.86 $38,480 - $53,948	18,863 Added 8.3%	246,080 $676,000
Q2 2024 Oct 17, 2024	BUY	$2.13 - $4.2 $90,580 - $178,609	42,526 Added 23.03%	227,217 $513,000
Q2 2024 Aug 14, 2024	BUY	$2.13 - $4.2 $90,580 - $178,609	42,526 Added 23.03%	227,217 $513,000
Q1 2024 Oct 17, 2024	SELL	$1.6 - $2.44 $68,041 - $103,763	-42,526 Reduced 18.72%	184,691 $441,000
Q1 2024 Aug 16, 2024	SELL	$1.6 - $2.44 $729 - $1,112	-456 Reduced 0.25%	184,691 $441,000
Q1 2024 May 15, 2024	SELL	$1.6 - $2.44 $729 - $1,112	-456 Reduced 0.25%	184,691 $441,000
Q4 2023 Aug 16, 2024	SELL	$1.6 - $2.18 $67,312 - $91,712	-42,070 Reduced 18.52%	185,147 $307,000
Q4 2023 Feb 13, 2024	BUY	$1.6 - $2.18 $620 - $845	388 Added 0.21%	185,147 $307,000
Q3 2023 Nov 15, 2023	SELL	$1.38 - $1.97 $448 - $640	-325 Reduced 0.18%	184,759 $354,000
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.08 $4,283 - $6,749	-3,245 Reduced 1.72%	185,084 $266,000
Q1 2023 May 15, 2023	BUY	$1.1 - $2.4 $164,520 - $358,953	149,564 Added 385.82%	188,329 $395,000
Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.66 $1,254 - $2,021	1,218 Added 3.24%	38,765 $43,000
Q3 2022 Nov 14, 2022	SELL	$1.31 - $2.48 $27,914 - $52,846	-21,309 Reduced 36.21%	37,547 $61,000
Q2 2022 Oct 27, 2022	SELL	$1.19 - $1.74 $5,537 - $8,096	-4,653 Reduced 7.33%	58,856 $77,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $1.74 $5,537 - $8,096	-4,653 Reduced 7.33%	58,856 $77,000
Q1 2022 Oct 27, 2022	BUY	$1.61 - $2.31 $7,491 - $10,748	4,653 Added 7.91%	63,509 $102,000
Q1 2022 May 13, 2022	SELL	$1.61 - $2.31 $47,968 - $68,824	-29,794 Reduced 31.93%	63,509 $102,000
Q4 2021 Feb 14, 2022	BUY	$2.07 - $3.8 $89,703 - $164,673	43,335 Added 86.73%	93,303 $194,000
Q3 2021 Nov 15, 2021	BUY	$2.59 - $4.15 $129,417 - $207,367	49,968 New	49,968 $195,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.65M

Call Options Held

1.16M

Put Options Held

1.98M

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $123M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account